KMDA - KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB® | Benzinga
- Since 2018 Kedrion has had exclusive distribution rights in the US for KEDRAB®, a Human Rabies Immune Globulin (HRIG) developed in partnership with Kamada Ltd.
- New agreement becomes effective in January 2024 and includes potential expansion of Kedrion's distribution of KEDRAB® in additional territories beyond the US
- Rabies is a global public health concern that is responsible for more than 59,000 human deaths per year in the world; an estimated 60,000 Americans receive Rabies post exposure prophylaxis each year
- Kedrion confirms its commitment to fighting Rabies and other serious and life-threatening diseases and conditions
CASTELVECCHIO PASCOLI, Italy, Dec. 7, 2023 /PRNewswire/ -- Kedrion Biopharma, a leading global biopharmaceutical company that develops, manufactures and commercializes therapeutic products derived from blood plasma, announces the execution of a binding memorandum of understanding with Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), an Israeli commercial stage global biopharmaceutical company and leader in the specialty plasma-derived field, for the amendment and the 8-year extension of the KEDRAB® US distribution agreement between the two companies.
KEDRAB® is a Human Rabies Immune Globulin (HRIG) developed in partnership with Kamada Ltd. Kedrion started the distribution of this product in the US in 2018.
This new commercial agreement, which begins in January 2024, includes potential expansion of Kedrion's distribution of KEDRAB® in additional territories beyond the US. ...